)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
CelLBxHealth
CelLBxHealth (CLBX) investor relations material
CelLBxHealth H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary15 Jul, 2026
Executive summary
Q2 2026 revenue doubled sequentially to £0.4 million, with H1 2026 revenue at £0.6 million, down from £0.8 million in H1 2025.
Gross margin improved to 61% in H1 2026 from 59% in H1 2025.
Operating loss for H1 2026 significantly reduced to £2.7 million from £9.7 million year-over-year.
Restructuring led to a 61% reduction in annualised burn rate and a leaner, more commercially focused business.
Strategic partnerships advanced with AstraZeneca, AdventHealth, QIAGEN, Roche Diagnostics, Illumina, and Myriad.
Financial highlights
Q2 2026 revenue: £0.4 million (100% increase over Q1 2026).
H1 2026 revenue: £0.6 million (H1 2025: £0.8 million).
Gross profit: £0.4 million (H1 2025: £0.5 million); gross margin: 61%.
Operating loss: £2.7 million (H1 2025: £9.7 million); loss after tax: £2.7 million (H1 2025: £9.3 million).
Cash and cash equivalents at 30 June 2026: £2.9 million (30 June 2025: £5.3 million).
Outlook and guidance
FY2026 revenues expected to be at least £2.1 million, representing at least 50% growth over FY2025.
Reduced operating cost base and improved cash utilisation provide runway into Q2 2027.
Commercial pipeline of £3.5 million supported by increased engagement from partners.
EBITDA positive expected in 2028, contingent on further revenue growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CelLBxHealth
- Revenue fell to £0.8m, but cost controls and new contracts support growth and cash runway into 2026.CLBX
H1 20258 Jul 2026 - FY2025 revenue was £1.4M, with cost cuts and partnerships driving targeted FY26 growth.CLBXQ4 2025 TU26 Jun 2026
- Restructuring and key partnerships set the stage for strong revenue growth and EBITDA targets.CLBXH2 202522 Jun 2026
- Restructuring and cost cuts drive a projected 50% revenue increase for FY 2026.CLBXQ1 2026 TU8 Jun 2026
- Fundraise, restructuring, and partnerships drive CTC diagnostics growth and target 2028 profitability.CLBXInvestor Update13 Apr 2026
- Revenue doubled and losses narrowed as commercial momentum builds and cash runway extends.CLBXH2 202320 Feb 2026
- Large pharma contracts and cost controls set the stage for growth and cashflow positive trading by 2026.CLBXH1 202420 Jan 2026
- Patented blood test isolates living tumor cells, enabling earlier, more precise cancer care.CLBXEmerging Growth Conference 7926 Dec 2025
- 31% revenue growth, major pharma wins, and strong pipeline with cash runway into Q1 2026.CLBXH2 202410 Nov 2025
CelLBxHealth
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage